Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
KZIA 
Kazia Therapeutics Ltd ADR (KZIA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: KZIA (1-star) is a SELL. SELL since 2 days. Simulated Profits (52.05%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $14.14
1 Year Target Price $14.14
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -24.11% | Avg. Invested days 33 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.88M USD | Price to earnings Ratio - | 1Y Target Price 14.14 |
Price to earnings Ratio - | 1Y Target Price 14.14 | ||
Volume (30-day avg) 1 | Beta 2.2 | 52 Weeks Range 2.86 - 39.05 | Updated Date 09/14/2025 |
52 Weeks Range 2.86 - 39.05 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -29.58 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -42029.54% |
Management Effectiveness
Return on Assets (TTM) -85.55% | Return on Equity (TTM) -3891.64% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6994050 | Price to Sales(TTM) 4.35 |
Enterprise Value 6994050 | Price to Sales(TTM) 4.35 | ||
Enterprise Value to Revenue 4.55 | Enterprise Value to EBITDA -0.71 | Shares Outstanding 1359620 | Shares Floating 422580635 |
Shares Outstanding 1359620 | Shares Floating 422580635 | ||
Percent Insiders 8.48 | Percent Institutions 8.91 |
Upturn AI SWOT
Kazia Therapeutics Ltd ADR
Company Overview
History and Background
Kazia Therapeutics Ltd is an Australian oncology-focused drug development company. Founded in 2003, it focuses on developing innovative therapies for cancer, primarily in areas with limited treatment options. It originally focused on diagnostics, transitioning its business model over time.
Core Business Areas
- Oncology Drug Development: Developing and commercializing novel oncology drugs. This includes discovery, preclinical studies, clinical trials, and potential commercialization.
Leadership and Structure
Kazia Therapeutics Ltd is led by an executive team with experience in pharmaceutical development and commercialization. The company has a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- Paxalisib: Paxalisib is a PI3K / AKT / mTOR pathway inhibitor being developed for glioblastoma, an aggressive brain cancer. Paxalisib has Orphan Drug Designation in the US for glioblastoma. Major competitors include standard treatments like temozolomide, and potential new therapies from companies like Karyopharm Therapeutics (XPOVIO) and DNAtrix (DNX-2401).
- Cantrixil: Cantrixil is a small molecule being developed for ovarian cancer. Competitors include standard chemotherapy regimens and targeted therapies from companies such as AstraZeneca (Lynparza) and Clovis Oncology (Rubraca).
Market Dynamics
Industry Overview
The oncology drug development market is a large and rapidly growing market, driven by increasing cancer incidence and advancements in treatment options. It is a highly competitive market with many players ranging from small biotechs to large pharmaceutical companies.
Positioning
Kazia Therapeutics Ltd is positioned as a niche player focused on developing innovative therapies for cancers with high unmet medical needs. Its competitive advantage lies in its novel drug candidates and targeted approach to drug development.
Total Addressable Market (TAM)
The TAM for glioblastoma is estimated to be in the billions of dollars globally. Kazia is positioned to capture a share through demonstrating effectiveness of its product candidates.
Upturn SWOT Analysis
Strengths
- Novel drug candidates with potential for improved efficacy and safety
- Experienced management team
- Focus on high unmet medical needs
- Orphan drug designation for paxalisib
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on clinical trial success
- Single asset pipeline concentration
- Vulnerability to negative trial results
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through acquisition or in-licensing
- Successful clinical trial results leading to regulatory approval
- Increased awareness and adoption of targeted therapies
Threats
- Competition from established therapies and other drug candidates
- Clinical trial failures
- Regulatory hurdles
- Patent expiration
Competitors and Market Share
Key Competitors
- MRK
- BMY
- ABBV
Competitive Landscape
Kazia is a small player relative to large pharma companies. It has innovative drugs, but is constrained by finances, compared to competitors with established revenue streams and marketing. Paxalisib is the key to gaining market share.
Growth Trajectory and Initiatives
Historical Growth: Kazia's growth has been driven by the advancement of its drug candidates through clinical trials.
Future Projections: Future growth is dependent on the success of ongoing clinical trials and potential regulatory approvals.
Recent Initiatives: Recent initiatives include advancing paxalisib through clinical trials for glioblastoma and other indications.
Summary
Kazia Therapeutics is a promising biotech company focused on oncology. Its strength lies in innovative drugs in clinical trials. Its main challenge is competition with large pharma. Success hinges on clinical trial outcomes for its key candidates, particularly Paxalisib.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst research
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data may be approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kazia Therapeutics Ltd ADR
Exchange NASDAQ | Headquaters Sydney, NSW, Australia | ||
IPO Launch date 1999-01-06 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | |
Full time employees - | |||
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in South Korea. Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase 3 clinical trial, for the treatment of glioblastoma, isocitrate dehydrogenase-mutant glioma, diffuse intrinsic pontine glioma, atypical teratoid/rhabdoid tumor, brain metastases, primary central nervous system (CNS) lymphoma, triple negative breast cancer, and ovarian cancer. The company also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3, which is in Phase 1 clinical trial, to treat advanced solid tumors. It has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, OIMR Berghofer Medical Research Institute, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, and Sovargen Co., Ltd. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.